VYNE Therapeutics (VYNE) Current Assets (2016 - 2026)

VYNE Therapeutics' Current Assets history runs 11 years deep, the most recent figure standing at $25.8 million for Q1 2026.

• Quarterly Current Assets fell 53.04% year-over-year to $25.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.8 million (down 53.04% YoY) and the FY2025 annual result came in at $30.0 million, down 53.43% from the prior year.
• Current Assets was $25.8 million for Q1 2026 at VYNE Therapeutics, down from $30.0 million in the prior quarter.
• Across five years, Current Assets topped out at $96.0 million in Q4 2023 and bottomed at $17.5 million in Q3 2023.
• A 5-year average of $52.0 million and a median of $48.1 million in 2022 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2023 — Current Assets slumped 60.24% — and 2024, when it soared 319.94%.
• VYNE Therapeutics' Current Assets stood at $38.3 million in 2022, then jumped by 150.72% to $96.0 million in 2023, then plunged by 32.85% to $64.4 million in 2024, then tumbled by 53.43% to $30.0 million in 2025, then retreated by 14.07% to $25.8 million in 2026.
• Business Quant data shows VYNE's Current Assets at $25.8 million in Q1 2026, $30.0 million in Q4 2025, and $44.3 million in Q2 2025.